Aspire BioPharma is trading at $6.91 (up 5%) as of July 21, 2026, continuing a two-day recovery following a period of significant downward pressure.
- The move appears driven by momentum and broader risk-on sentiment, notably outperforming the wider biotech sector as major indices trade lower.
- The company recently solidified its financial position and Nasdaq listing compliance through a $21 million Series A private placement and a $22.5 million credit facility commitment.
- While no new catalysts were reported today, the stock is gaining traction as it recovers from its prior sharp selloff.